In our study, we have unexpectedly discovered a novel scenario in which aberrant activation of NF-κB and JNKs in cancer cells is acquired upon the loss of a pro-inflammatory molecule—IL-17RC, and an anti-inflammatory molecule—A20. This evidence concerns the gene IL17RC and cancer.